Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab 8-Week vs 12-Week Initial Follow-Up in Wet AMD
NCT06875245Phase 4Recruiting
- Sponsor
- Faculty Hospital Kralovske Vinohrady
- Start
- Mar 2023
- Primary completion
- Apr 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of faricimab in exudative macular degeneration, sponsored by Faculty Hospital Kralovske Vinohrady. Started Mar 2023; status: recruiting.
02
Drugs
faricimab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT06875245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06875245.